These engaging presentations offer practical instruction on type 2 diabetes mellitus pathophysiology, early diagnosis, goals of therapy and care, novel treatments, management of hypertension and dyslipidemia, patient monitoring, and treatment guidelines. In addition, these activities will touch on recent controversies relating to measurement and application of HbA1c levels, inconsistencies between current T2DM guidelines, and intensive versus standard therapy.

Learn about the relationship between HbA1c and glycemia, the risks and benefits of treatment in general and intensive glycemic control in particular, the physiologic defects that lead to chronic hyperglycemia in T2DM, and whether or not diabetic patients remain vulnerable to microvascular and macrovascular complications even when blood sugar is well controlled.

New and emerging therapies are also covered, including SGLT-2 inhibitors (how they work, what they can achieve, their safety profile, and their potential role in the management of T2DM) and incretin-based therapies, including GLP-1 agonists/analogs and DPP-4 inhibitors (their mechanisms of action, and safety and efficacy data).

A case study is presented to illustrate how to individualize HbA1c targets, selection of initial treatment, and considerations for choosing among the numerous options now available or emerging for add-on therapy in patients who have not met treatment goals with monotherapy.

Each presentation offers free CME, CE, and CPE credit to diabetologists, endocrinologists, internists, primary care physicians, nurse practitioners, nurses, and pharmacists who participate in the care of patients with type 2 diabetes.